






Outline

## Suspect synovial involvement, now what?

- Determine what structures are involved and severity of involvement
  - Bone surfaces
    - Periosteum, cortex, endosteum, fracture, physis
  - Synovial surfaces · Joint, tendon sheath, bursa
  - Soft tissues
  - Skin, SQ, neurovasculature, tendons, ligaments
  - Implant/foreign bodies






- +/- intracellular bacteria
- Sterile skin preparation and needle placement
- 18 gauge needle
- Sterile EDTA tube (purple)






7






11



10

8






## General Guidelines for Treatment


- Lavage
- Debride
- Antimicrobials
- Anti-inflammatories
- Usually need multiple modalities of treatment
- Aggressive early treatment essential
- Kill bacteria at presentation
- Resolve inflammation following resolution of infection


KANSAS STATE

17



18







Arthrotomy/Thecotomy


- Provides continuous drainage
- Option for synovial structures with high volume fibrin
- Must have sterile bandage


   Difficult in stifle/upper limb

















## **Regional Perfusion**

Intra-venous

- Achieved high concentrations of drug in synovial structures and surrounding tissue
- Reduced drug expense and toxicity
- Good when there is significant soft tissue trauma
- Tourniquet placed proximal to site of infection
- Small butterfly catheter (23G)
- 500 mg-1 gram amikacin QS to 35-60ml (depending on location and foal vs. adult)
- 20-30 minutes for diffusion
- Every other day or until satisfied infection is eliminated
- Standing or under anesthesia during surgical procedure
- Avoid arteries due to risk of thrombosis or phlebitis

KANSAS STATE

33



**Regional Perfusion Antimicrobial** 

**Properties** 

Amikacin (aminoglycoside) is the most


**Concentration Dependent** 


Bactericidal

common!!


36

34







35



KANSAS STATE





O'Brien, EVJ,

nt, EVJ,

no other sys dz) 93%

65%

Higher last TNCC of

synovial fluid

Lower earning from septic jt.

Foals (KY)

95 115 (TB, single joint, (TB, ≤ 180 days)

78%

67%

<26 days old,

multisystemic

osetomyelitis

No difference in

racing potential

(Australia)

disease,

Wright, EVE,

60 (<u><</u> 60 days old)

80%

67%

62%

None found

Trends (not

significant):

time to

treatment

Increased # joints, increased 83 (<u><</u> 180 days old)

Number of

MANSAS SIAIL

joints affected

57%

40

# of cases

Short-term

Long-term

survival

survival


Athletic

Negative

Prognostic indicators

42

performance



41



